Tip I hepatorenal sendromda terlipressin tedavisi: 6 olgu
Terlipressin treatment in type I hepatorenal syndrom: 6 cases
Özet
Giris ve amaç: Tip 1 hepatorenal sendrom (HRS) sirozun önemli komplikasyonudur. Terlipressin kullanimi böbrek fonksiyonlarini düzeltmektedir. Bu çalismada yan etkiler az olan vazopressin anologu terlipressin ile albumin kullaniminin HRS’da etkileri degerlendirilmistir. Gereç ve yöntem: Tip 1 HRS tespit edilen 6 olgu terlipressin ve albumin ile tedavi edildi. Terlipressin (4 mg/gün) 3 gün süreyle albumin (20 mg/gün) 5 gün süreyle 6 olguda uygulandi. Bulgular: Böbrek fonksiyonlarinda düzelme 5 olguda izlenirken (serum kreatinin 3.4 den 1,6 mg/dl’e azaldi, 24 saatlik idrar miktari 81 ml’den 890 ml’ye çikti), 1 aylik yasam süresi % 83 olarak bulundu. Sonuç: Bu çalismanin sonuçlari terlipressin uygulanmasi ile böbrek fonksiyonlarini düzelttigini ve yasam sürelerini uzatti gini göstermektedir.
Abstract
Background and aims: Type 1 hepatorenal syndrome (HRS) is a severe complication of cirrhosis. Administration of terlipressin improves renal function, but its effect on survival is unknown. The aim of this study was to assess the efficacy of terlipressin, an analog of vasopressin with a low profile of side effects, plus albumin in this condition. Material and methods: Six patients with type 1 HRS were treated with terlipressin plus albumin. Terlipressin (4 mg/day) was administered for 3 days and albumin (20 mg/d) for 5 days. Results: Renal function improved in 5 patients (serum creatinine decreased to 1.6 mg/dl from 3.4 mg/dl, and 24 hour urine volume increased to 890 ml from 81 ml). Survival rate was 83% at 1 month. Conclusions: This study shows that in patients with type 1 HRS, terlipressin-induced improved renal function is associated with an increase in survival.
